Athira Pharma Shares Fall To 52-Week Low – Read Why
Athira Pharma Inc (NASDAQ:ATHA) shares are falling to 52-week lows after announcing disappointing topline results from its exploratory ACT-AD Phase 2…
Related Posts
JP Morgan Maintains Overweight on Carlyle Group, Lowers Price Target to $45
JP Morgan analyst Kenneth Worthington maintains Carlyle Group (NASDAQ:CG) with a Overweight and lowers the price target from $53 to $45.
Zynerba Stock Moves Higher On Long-Term Zygel Data In Autistic Children
Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) presented data from the Phase 2 BRIGHT trial of Zygel in children and adolescents with…
Benchmark Initiates Coverage On iQIYI with Hold Rating
Benchmark analyst Fawne Jiang initiates coverage on iQIYI (NASDAQ:IQ) with a Hold rating.